LMEN Review: Answers to commonly asked questions about biosimilar versions of infliximab

· London and South East Regional Medicines Information Service

The first biosimilar versions of infliximab were approved for use in Europe in October 2014 and are due to be launched in the UK in late February 2015. This means that there will be three brands of infliximab available to prescribers in the UK and they will all be licensed identically to the originator product for use in ankylosing spondylitis, rheumatoid and psoriatic arthritis, psoriasis and inflammatory bowel disease (Crohn’s disease and ulcerative colitis). This briefing sheet is intended to support prescribers by providing answers to commonly asked questions about the introduction of these medicines.